title: The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants.
abstract: Phase-sensitive in situ forming implants (ISFI) are a promising platform for the controlled release of therapeutic agents. The simple manufacturing, ease of placement, and diverse payload capacity make these implants an appealing delivery system for a wide range of applications. Tailoring the release profile is paramount for effective treatment of disease. In this study, three innovative formulation modifications were used to control drug release. Specifically, water, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI), and bovine serum albumin (BSA) were incorporated into an ISFI solution containing the small molecular weight mock drug, sodium fluorescein. The effects of these additives on drug release, swelling, phase inversion, erosion, and implant microstructure were evaluated. Diagnostic ultrasound was used to monitor changes in swelling and phase inversion over time noninvasively. Water, DiI, and the combination of BSA/DiI functioned to reduce burst release 47.6%, 76.6%, and 59.0%, respectively. Incorporation of water into the casting solution also enhanced the release of drug during the diffusion period of release by 165.2% relative to the excipient free control. Incorporation of BSA into the polymer solution did not significantly alter the burst release (p < 0.05); however, the onset of degradation facilitated release was delayed relative to the excipient-free control by 5 days. This study demonstrates that the use of excipients provides a facile method to tailor the release profile and degradation rate of implants without changing the polymer or solvent used in the implant formulation, providing fine control of drug dissolution during distinct phases of release.
authors.affiliation: Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, 48109.
authors.forename: Luis
authors.initials: L
authors.lastname: Solorio
authors.affiliation: School of Medicine, New York Medical College, Valhalla, New York, 10595.
authors.forename: Divya
authors.initials: D
authors.lastname: Sundarapandiyan
authors.affiliation: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, 44106.
authors.forename: Alex
authors.initials: A
authors.lastname: Olear
authors.affiliation: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, 44106.|Department of Radiology, Case Western Reserve University, Cleveland, Ohio, 44106.
authors.forename: Agata A
authors.initials: AA
authors.lastname: Exner
mesh_terms: D002232:Carbocyanines; D002626:Chemistry, Pharmaceutical; D004343:Drug Implants; D005079:Excipients / Q000737:chemistry*; D019793:Fluorescein / Q000737:chemistry; D008970:Molecular Weight; D012710:Serum Albumin, Bovine / Q000737:chemistry; D012995:Solubility; D014465:Ultrasonics
chemical_list: D002232:Carbocyanines; D004343:Drug Implants; D005079:Excipients; D012710:Serum Albumin, Bovine; C024286:3,3'-dioctadecylindocarbocyanine; D019793:Fluorescein
keywords: Biomaterials; Casting; Controlled release; Drug delivery systems; Encapsulation; Excipients; Image analysis; Injectables; Phase transition; Ultrasound